Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Active not recruiting 7Withdrawn 3Terminated 3Not yet recruiting 1No longer available 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 3Plasma cell 1

Conditions

Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Rituximab 55Cyclophosphamide 45Vincristine 23fludarabine phosphate 21Cytarabine 20fludarabine 19Etoposide 19Prednisone 18Bendamustine Hydrochloride 18ibrutinib 17Methotrexate 17Doxorubicin 17Lenalidomide 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13Filgrastim 12venetoclax 11Melphalan 11Dexamethasone 11Whole-Body Irradiation 8Tacrolimus 8Busulfan 8Brentuximab Vedotin 8Biopsy 8pembrolizumab 7duvelisib 7Nivolumab 7Mycophenolic Acid 7Gemcitabine 7Cyclosporine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × AP 1903 reagent × Lymphoid × Clear all
NCT02487459 2020-10-05

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Bellicum Pharmaceuticals

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Bellicum Pharmaceuticals

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT03807063 2020-08-14

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡